TABLE 1.

Patient Characteristics and Lung Function at Baseline

Number of Patients
HFA−BDP 100–200 μg (n = 183)CFC−BDP+S 200–400 μg (n = 64)
Male/female (%)130/53 (71.0/29.0)47/17 (73.4/26.6)
Age (y)*
 Mean (SD)8.65 (1.766)8.42 (1.550)
 Range5.3–12.15.3–12.0
Duration of asthma (%)
 <1 y8 (4.4)1 (1.6)
 1–5 y104 (56.8)35 (54.7)
 >5 y70 (38.3)27 (42.2)
 Unknown1 (0.5)1 (1.6)
Height (cm)
 Mean (SD)131.79 (11.204)131.33 (11.128)
 Range109.0–157.5108.3–157.9
am PEF (L/min; mean [SD])253.7 (62.47)255.8 (62.84)
FEV1 (% predicted; mean [SD])88.8 (13.69)90.4 (12.87)
Days without symptoms (%; mean [SD])
 Wheeze86.7 (29.62)83.3 (29.74)
 Cough70.4 (36.80)72.2 (36.51)
 Shortness of breath90.1 (25.01)84.9 (26.68)
 Chest tightness91.3 (22.48)83.4 (29.89)
Nights without sleep disturbance (%; mean [SD])92.1 (20.07)89.1 (24.26)
Daily β-agonist use (puffs; mean [SD])1.2 (1.85)1.1 (1.73)
  • SD indicates standard deviation.

  • * According to the study inclusion criteria, patients were aged 5 to 11 years, and this was confirmed at the screening visit. Baseline measures were assessed after a 4-week run-in phase; hence, some children had reached their 12th birthday by study baseline.